Saskatchewan SARS-CoV-2 Seroprevalence Study
Networks
-
Datasets
-
Variables
-
The primary objective of this study is to measure the seroprevalence of antibodies to COVID-19 in Saskatchewan by geographic area, age group and sex in order to ascertain the cumulative population immunity.
Secondary objectives of this study are:
* To target immunization priorities to areas of the province with low seroprevalence rates,
* To estimate the fraction of vaccine-induced immunity versus natural infection,
* To examine duration of protection at a population-level by analyzing the association between antibody titer levels and length of time since immunization,
* To compare provincial population immunity to SARS-CoV-2 pre and post-immunization and pre and post Variant of Concern (VoC) importation.
- Start Year
- 2020
- End Year
- 2023
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cross-sectional
- Follow Up
- A random sample of serum collected for the purposes of TSH and Cholesterol testing in the province of Saskatchewan during two time periods, Phase 1 from May to December 2020 and Phase 2 from October 2021 to June 2022, will be tested for antibodies to SARS-CoV-2.
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- 20,000
- Number of Participants with Biological Samples
- 20,000
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Timeline
SaskCov population
The population is composed of individuals who have their blood samples collected for the purposes of TSH and Cholesterol testing from laboratories across Saskatchewan.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Saskatchewan
- Ethnic Origin
-
- Health Status
-
- Supplementary Information about selection criteria
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
A random selection of residual serum samples collected for the purposes of TSH and Cholesterol testing will be analyzed for antibodies to SARS-CoV-2.
Number of Participants
- Number of Participants
- 20,000
- Number of Participants with Biological Samples
- 20,000
- Supplementary Information about selection criteria
-
Phase I collection: 10,000 samples
Phase II collection: 10,000 samples
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
SaskCov - Phase I Collection
|
A random selection of serum samples was collected and will be tested for antibodies to SARS-CoV-2. Approximately 300 samples that test positive for antibodies to SARS-CoV-2 will undergo ... | 2020-05 | 2020-12 |
| 1 |
SaskCov - Phase II Collection
|
A random selection of serum samples was collected and will be tested for antibodies to SARS-CoV-2. Approximately 300 samples that test positive for antibodies to SARS-CoV-2 will undergo ... | 2021-10 | 2022-06 |
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
Socio-demographic and economic characteristics
Sex/gender
Laboratory measures
Virology
Administrative information
Identifiers
Date and time-related information
Physical and cognitive measure and biosample-related information